Polybrominated dibenzo-p-dioxins, dibenzofurans, and biphenyls: inclusion in the toxicity equivalency factor concept for dioxin-like compounds

• Published in: Toxicological sciences 2013-06, Vol.133 (2), p.197-208
• Main Authors: van den Berg, Martin, Denison, Michael S, Birnbaum, Linda S, Devito, Michael J, Fiedler, Heidelore, Falandysz, Jerzy, Rose, Martin, Schrenk, Dieter, Safe, Stephen, Tohyama, Chiharu, Tritscher, Angelika, Tysklind, Mats, Peterson, Richard E
• Format: Article
• Language: English
• Subjects: Animals; Benzofurans - pharmacokinetics; Benzofurans - toxicity; biomarkers; Dioxin; Dioxins - pharmacokinetics; Dioxins - toxicity; Dose-Response Relationship, Drug; Environmental Exposure; Environmental Monitoring - methods; halogenated hydrocarbon; Humans; persistent organic chemicals; Polybrominated Biphenyls - pharmacokinetics; Polybrominated Biphenyls - toxicity; polychlorinated biphenyls; regulatory/policy; Review; Risk Assessment; Soil Pollutants - pharmacokinetics; Soil Pollutants - toxicity; Toxicity Tests
• ISSN: 1096-6080; 1096-0929; 1096-0929
• DOI: 10.1093/toxsci/kft070

In 2011, a joint World Health Organization (WHO) and United Nations Environment Programme (UNEP) expert consultation took place, during which the possible inclusion of brominated analogues of the dioxin-like compounds in the WHO Toxicity Equivalency Factor (TEF) scheme was evaluated. The expert panel concluded that polybrominated dibenzo-p-dioxins (PBDDs), dibenzofurans (PBDFs), and some dioxin-like biphenyls (dl-PBBs) may contribute significantly in daily human background exposure to the total dioxin toxic equivalencies (TEQs). These compounds are also commonly found in the aquatic environment. Available data for fish toxicity were evaluated for possible inclusion in the WHO-UNEP TEF scheme (van den Berg et al., 1998). Because of the limited database, it was decided not to derive specific WHO-UNEP TEFs for fish, but for ecotoxicological risk assessment, the use of specific relative effect potencies (REPs) from fish embryo assays is recommended. Based on the limited mammalian REP database for these brominated compounds, it was concluded that sufficient differentiation from the present TEF values of the chlorinated analogues (van den Berg et al., 2006) was not possible. However, the REPs for PBDDs, PBDFs, and non-ortho dl-PBBs in mammals closely follow those of the chlorinated analogues, at least within one order of magnitude. Therefore, the use of similar interim TEF values for brominated and chlorinated congeners for human risk assessment is recommended, pending more detailed information in the future.